Matthew Gline

Matthew Gline has an estimated net worth of $547 Million. This is based on reported shares across multiple companies, which include Roivant Sciences Ltd., and Arbutus Biopharma Corp.

2023 was Matthew Gline's most active year for acquiring shares with 5 total transactions. Matthew Gline's most active month to acquire stocks was the month of November. 2023 was Matthew Gline's most active year for disposing of shares, totalling 24 transactions. Matthew Gline's most active month to dispose stocks was the month of November. 2025 saw Matthew Gline paying a total of $47,112,005.65 for 3,873,974 shares, this is the most they've acquired in one year. In 2025 Matthew Gline cashed out on 7,796,721 shares for a total of $84,514,805.17, their largest year based on trade value.